Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | approved for marketing | — | — | Janssen Biotech, Inc.INDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT05172700 | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | approved for marketing | — | — | Loxo Oncology, Inc.INDUSTRY | 0 | Dec 18, 2024 | clinicaltrials |
| NCT04162756 | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies(ZUMA-18) | approved for marketing | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Feb 3, 2025source: clinicaltrials